Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TAK-672 · 1 trial · 1 indication
Percentage of severe bleeding episodes with demonstrated response to TAK-672 therapy at 24 hours after the initiation of treatment was assessed by using a well-defined 4-point ordinal scale - A 'positive response' was defined as 'effective' (bleeding stopped with clinical control and FVIII:C levels of 50% or higher ) or 'partially effective' (bleeding reduced with clinical stabilization and FVIII:C levels of 20% or higher) control of bleeding, as determined by the investigator using a 4-point rating scale (effective - partially effective - poorly effective - not effective). 'Poorly effective' was defined as 'bleeding slightly reduced or unchanged and FVIII:C levels of less than 50%'. 'Not effective' was defined as 'bleeding worsening and FVIII:C levels of less than 20%'.
| Arm | Type | Description |
|---|---|---|
| TAK-672 | EXPERIMENTAL | TAK-672 was administered at an initial dose of 200 U/kg with IV infusion at a rate of 1-2 mL/min at Day 1. Subsequent doses were determined based on the post-infusion FVIII:C achieved after the most recent dose given, the target FVIII:C, and pFVIII inhibitor titer. |
| Name | Type | Description |
|---|---|---|
| TAK-672 | BIOLOGICAL | B-Domain Deleted Recombinant Porcine Factor VIII |
Inclusion Criteria: 1. Male or female Japanese participants of \>=18 years of age. 2. Participants who (or their legally authorized representatives) have provided his/her written informed consent form prior to any study-related procedures and study product administration. 3. Participants with a dia...
TAK-672 is an investigational monoclonal antibody being developed for the treatment of acquired hemophilia A, a rare bleeding disorder. It is currently in Phase 2 clinical development and has been studied in a completed clinical trial.
TAK-672 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The drug is an investigational monoclonal antibody for acquired hemophilia A and is currently in Phase 2 clinical development.
TAK-672 is in Phase 2 clinical development. It is an investigational monoclonal antibody for acquired hemophilia A and has not been approved by regulatory authorities. One Phase 2 trial of TAK-672 has been completed.
TAK-672 has been studied in a completed Phase 2 clinical trial with the identifier NCT04580407. This trial, titled "Study of TAK-672 in Participants With Acquired Hemophilia A," enrolled 5 participants in Japan and included adults aged 18 years and older.
Yes, TAK-672 is a monoclonal antibody. It is being developed by Takeda Pharmaceutical Company Limited for the treatment of acquired hemophilia A and is currently in Phase 2 clinical development.